Sarepta Therapeutics Investors Urged to Act Before Class Action Deadline

Important Investor Update: Deadline Approaching for Sarepta Therapeutics Class Action Lawsuit

Attention to all investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT): a critical window to engage in a class action lawsuit is nearing its end. If you have acquired Sarepta securities between June 22, 2023, and June 24, 2025, you may be eligible to become the lead plaintiff in this significant legal proceeding against the company. The class action case, formally titled Dolgicer v. Sarepta Therapeutics, Inc., and numbered 25-cv-05317 in the Southern District of New York, brings allegations against Sarepta and its executives for violations of the Securities Exchange Act of 1934.

Background on Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biotech firm primarily focused on developing innovative therapies for rare muscular diseases, particularly Duchenne muscular dystrophy (Duchenne). The company’s key product, ELEVIDYS, is a gene therapy designed for Duchenne patients, targeting a very specific patient demographic.

However, the lawsuit claims that throughout the designated class period, Sarepta made several misleading statements regarding ELEVIDYS, failing to disclose critical safety concerns. Notably, the suit alleges that:

- ELEVIDYS was associated with serious safety risks, which were not disclosed to investors.
- Clinical trial regimes were inadequate and missed detecting severe side effects.
- The adverse effects associated with ELEVIDYS led the company to halt trials and face increased regulatory scrutiny, jeopardizing the therapy's approval.

This situation escalated on March 18, 2025, when Sarepta disclosed that a patient had suffered acute liver failure resulting from ELEVIDYS treatment, which unfortunately led to death. This revelation prompted a startling drop in Sarepta’s stock price by over 27% on the news. Additional disclosures on April 4 and June 15, 2025, regarding further patient fatalities and regulatory actions, continued to negatively impact the company’s financial standing, causing further stock declines of 7% and 42% respectively.

Moreover, following the FDA's public safety communication regarding two patient deaths attributed to ELEVIDYS, Sarepta’s stock witnessed another drop of over 8%.

Legal Processes and Initiatives

The Private Securities Litigation Reform Act of 1995 allows any investor who suffered losses during the stated acquisition period to seek lead plaintiff status in the ongoing class action lawsuit. The role of a lead plaintiff is crucial, as this individual represents the interests of the affected investors and directs the legal processes.

If you believe that you are eligible and wish to step into the lead plaintiff position, time is of the essence. All interested parties must act by August 25, 2025. Interested investors can provide their information directly through the designated attorneys at Robbins Geller Rudman & Dowd LLP, who are handling the case.

For further assistance or to submit your information, investors can reach out to attorneys J.C. Sanchez or Jennifer N. Caringal at 800-449-4900 or via email at [email protected]

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is a leading law firm renowned for securing substantial recovery for investors embroiled in securities fraud and shareholder litigation. The firm boasts an impressive track record, recovering over $2.5 billion for investors in recent years, making them a formidable ally for aggrieved shareholders.

As this situation unfolds, it is imperative for affected investors to remain vigilant and consider taking action. By doing so, you may influence the trajectory of this class action lawsuit significantly. For more information on investor rights and the ongoing lawsuit, visit Robbins Geller’s website.

The landscape of securities litigation is complex, and while past recoveries do not guarantee future outcomes, being informed and proactive can change the prospects for many investors.